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Abstract
Background: Persistent throat symptoms and Extra Oesophageal Reflux (EOR) are among the commonest reasons
for attendance at a secondary care throat or voice clinic. There is a growing trend to treat throat symptom patients
with proton pump inhibitors (PPIs) to suppress stomach acid, but most controlled studies fail to demonstrate a
significant benefit of PPI over placebo. In addition, patient views on PPI use vary widely.
Methods/design: A UK multi-centre, randomised, controlled trial for adults with persistent throat symptoms to
compare the effectiveness of treatment with the proton pump inhibitor (PPI) lansoprazole versus placebo.
The trial includes a six-month internal pilot, during which three sites will recruit 30 participants in total, to assess the
practicality of the trial and assess the study procedures and willingness of the patient population to participate. If the
pilot is successful, three additional sites will be opened to recruitment, and a further 302 participants recruited across
the six main trial sites. Further trial sites may be opened, as necessary. The main trial will continue for a further 18
months. Participants will be followed up for 12 months from randomisation, throughout which both primary and
secondary outcome data will be collected. The primary outcome is change in Reflux Symptom Index (RSI) score, the
‘area standard’ for this type of assessment, after 16 weeks (four months) of treatment. Secondary outcomes are RSI
changes at 12 months after randomisation, Quality of Life assessment at four and 12 months, laryngeal mucosal
changes, assessments of compliance and side effects, and patient-reported satisfaction.
Discussion: TOPPITS is designed to evaluate the relative effectiveness of treatment with a proton pump inhibitor
versus placebo in patients with persistent throat symptoms. This will provide valuable information to clinicians and
GPs regarding the treatment and management of care for these patients, on changes in symptoms, and in Quality
of Life, over time.
Trial registration: ISRCTN38578686. Registered 17 April 2014.
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Background
Trial Of Proton Pump Inhibitors in Throat Symptoms
(TOPPITS) addresses the problem of adults with persistent
throat symptoms such as globus, catarrh, throat discomfort,
clearing, recurring dysphonia or excess mucus. In one UK
survey, 6 % of the middle-aged female population had had
a persistent feeling of the something in the throat (globus)
in the previous 3 months [1]. Globus is also reported to
account for up to 4 % of ear, nose and throat (ENT) refer-
rals to secondary care [2]. Throat clearing is the common-
est single symptom in any voice clinic. Equally familiar are
intermittent hoarse voice and postnasal drip [3]. It is
claimed that 55 % of patients referred to a voice clinic have
symptoms of extra oesophageal reflux (EOR), while an Eng-
lish study of primary care attenders indicated that 25 % had
recent experience of persistent upper respiratory symptoms
[4]. In the general population, the lifetime incidence of
milder variants of globus (a feeling of a lump in the throat)
is over 40 % [5]. In 2010–2011, the Hospital Episode Statis-
tics online database of National Health Service (NHS) activ-
ity lists 1,142,404 first ENT consultations. A conservative
estimate is that 5 % of these patients were referred for very
common throat symptoms like throat clearing, fluctuating
voice change, catarrh and chronic throat discomfort, which
equates to over 57,000 NHS patients referred to secondary
care that year in England alone. Some patients experience
anxiety as they fear they may have throat cancer. Even if
they have no features and no risk factors for cancer, they
may be referred for urgent ENT clinic assessment—a
process which prolongs the anxiety, and at times the symp-
toms. In the absence of good quality treatment algorithms,
patients also undergo invasive and costly assessments such
as rigid endoscopic examination of the upper aerodigestive
tract under general anaesthesia, which typically reveals no
significant abnormality, and empiric trials of acid suppres-
sion, typically with proton pump inhibitors (PPIs).
EOR symptoms have long been recognised as having a
strong placebo response [6]. The original evidence that
reflux might affect the upper airway came from animal
experiments, and the term ‘acid laryngitis’ was coined 40
years ago [7]. Intracellular reactivation of acidified pepsin
may explain pepsin activity at weakly acid pH [8, 9]. There
is a growing trend to treat throat symptom patients empir-
ically with PPIs, but most controlled studies fail to demon-
strate a significant benefit of PPI over placebo [10, 11, 12].
Our UK Evidence Based Medicine EOR conference con-
cluded that: ‘Studies assessing PPIs in EOR suffer from vari-
able study design and quality, small numbers and heavy
selection bias and use a variety of different treatment
regimes. The small proportion of controlled studies demon-
strating overall benefit of PPI over placebo [13] may incorp-
orate a disproportionate improvement in heartburn, known
to respond promptly to antacid therapies, without due
regard to the upper airway symptoms per se’ [14, 15]. There
was little evidence on other pharmaceuticals such as H2
antagonists [16, 17]. In the Patient and Public Involvement
background work for this proposal, individual interviews
were conducted with several patients encompassing both
young professionals and retired patients. All interviewees
fully supported the research proposal. It was also clear, even
from a small sample, that patient views on PPIs vary widely
but all of them had been treated at some point with PPIs,
sometimes on more than one occasion.
Methods and design
Aim
This is a non-commercial study to determine the clinical
effectiveness of the PPI lansoprazole compared with pla-
cebo, in patients referred to secondary care with persistent
throat symptoms.
Objectives
The primary objective is to compare the symptomatic re-
sponse in patients with persistent throat symptoms at the
end of 4 months (16 weeks) of treatment with lansoprazole
versus placebo.
Secondary objectives are as follows:
1. To explore the feasibility of study recruitment by
means of an internal pilot trial rehearsal whose data
will be included in the main data for analysis.
2. To compare the symptom response at the end of 4
months (16 weeks) of treatment with those at 12
months.
3. To determine the utility of the Reflux Symptom Index
(RSI) questionnaire, the Comprehensive Reflux
Symptom Score (CReSS) questionnaire items and
subscales, endolaryngeal examination findings as
scored by the Reflux Finding Score (RFS) and patient
demographics including age, gender, smoking and
body mass index [18–20] as potential baseline
determinants of treatment response. (Hence
generating improved characterisation of the subgroup
of suspected laryngopharyngeal reflux (LPR) patients
most likely to benefit from acid suppression therapy.)
4. To compare the patient-reported side effects and
compliance with treatment and use of any other
over-the-counter medication use in both arms.
5. To compare changes in disease-specific quality of
life—Laryngopharyngeal Reflux Health-related Qual-
ity of Life (LPR-HRQL)—in the two arms.
Study setting
Participants for the internal pilot will be recruited from
three UK hospitals: The Freeman Hospital in Newcastle
upon Tyne (The Newcastle upon Tyne Hospitals NHS
Foundation Trust), Sunderland Royal Hospital (City Hos-
pitals Sunderland NHS Foundation Trust) and Queen’s
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Medical Centre in Nottingham (Nottingham University
Hospitals NHS Trust).
On completion of the internal pilot, it is planned that a
further three UK sites will participate in the main trial:
Royal Sussex County Hospital in Brighton (Brighton and
Sussex University Hospitals NHS Trust), Glasgow Royal
Infirmary (NHS Greater Glasgow and Clyde) and Manches-
ter Royal Infirmary (Central Manchester University Hospi-
tals NHS Foundation Trust). A further site has also opened:
New Queen Elizabeth Hospital, Birmingham (University
Hospitals Birmingham NHS Foundation Trust)
If necessary, further sites will be activated as trial recruit-
ing centres.
Target population and sample size
Participants will be adult patients newly referred to second-
ary care otolaryngology clinics with persistent (for over 6
weeks) unexplained throat symptoms, principally dyspho-
nia, throat pain, globus sensation (feeling of something
stuck in the throat), throat clearing, postnasal drip or mucus
excess, and also night-time unexplained cough or choking.
Inclusion criteria
 Referred with a persistent (over 6 weeks) primary
throat symptom—globus, hoarseness, throat clearing,
throat discomfort, choking spasms, excess mucus/
postnasal drip or otherwise unexplained night-time
cough or choking. Score of 10 or more on the non-
heartburn items of the RSI.
 Patient has the capacity to provide fully informed
consent to participate in the study.
Exclusion criteria
 Those patients with an RSI score excluding the
lower gastrointestinal (GI) item of <10.
 Patients who are not willing to undergo flexible
endoscopy could not by definition be included.
 Inability to complete the relevant questionnaires.
 Patients younger than 18 years old.
 Endoscopic evidence of specific laryngopharyngeal
pathology that would ordinarily be treated by surgical
intervention or be investigated by specific
investigations. This includes suspected neoplasia/
dysplasia, prominent Reinke’s oedema or unilateral
vocal fold polyp and vocal cord palsy, and rarities
such as amyloid, Wegener’s and sarcoid granuloma.
 Confirmed or likely, current or prior malignancy of
the head and neck or oesophagus.
 Performing voice users including singers, actors and
media workers (e.g. voice-over artists, radio DJs).
 Pregnant or lactating woman. Woman of child-bearing
potential must be using adequate contraception.
 Currently on acid suppressants, acid neutralisers and
alginates and unwilling to discontinue for a 4-week
pre-study washout period (PPI); 24 hours for alginate
or acid neutraliser. For those discontinuing PPI, ad
hoc alginate use is allowed until the final 24–48 hours
of the washout period prior to reassessment.
 Prior adverse reaction to PPI.
 Severe hepatic dysfunction.
 Patients taking clopidogrel or warfarin.
 Patients taking phenytoin.
 Patients taking systemic antifungal treatment
(specifically itraconazole, ketoconazole,
posaconazole, voriconazole).
 HIV-positive patients/patients taking antiviral
medications (atazanavir, nelfinavir, raltegravir,
saquinavir, tipranavir).
 Patients taking digoxin, cyclosporine, methotrexate,
erlotinib, lapatinib, tacrolimus, sucralfate,
escitalopram, fluvoxamine, St John’s wort, clozapine,
ulipristal or cilostazol.
 Previous participation in this study.
 Use of other investigational study drugs within 30
days prior to study entry.
Screening, recruitment and consent
Identification and screening of participants
Potential participants may be identified through routine
clinic outpatient appointments by their treating physician
(the principal investigator (PI) at site, or a colleague). The
PI and colleagues will ensure that all clinicians at each site
are informed about the nature and purpose of TOPPITS, to
enhance recruitment.
At the initial clinic appointment a routine consultation
and clinical examination will take place. Any patient with
persistent throat symptoms will be asked to complete the
RSI form, and the total minus the heartburn item will be
computed. If a patient scores 10 or more non-heartburn
items the physician will inform the patient of the trial and
offer them participation.
If a patient scores 10 or more on the RSI—Heart Burn,
and is interested in the TOPPITS concept, a participant
information sheet (PIS) will be given with an opportunity
to view a DVD explaining study procedures (see
Additional file 1). The potential participant will be invited
to attend the dedicated TOPPITS clinic at a subsequent
date convenient for them. The details of such patients will
be passed to the TOPPITS research nurse to arrange a
convenient appointment. A screening log will be produced
which will be filled in for all potential participants
screened, including reason for ineligibility and/or refusal
to participate.
Potential participants may also be screened using
their primary care referral letters. The PIs at site will be
responsible for sending out an invitation letter and PIS
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in the post, detailing the study. These patients will be
booked straight onto a TOPPITS trial clinic.
Recruitment
Eligible patients who have received the PIS through the rou-
tine clinic outpatient appointment or through the invite
process will then attend a dedicated TOPPITS trial clinic,
where any outstanding queries will be answered, followed
by an invitation to participate from the consultant or re-
search nurse. They will have all already have received the
PIS and a study DVD. They will be given time to discuss
the study further in this clinic. At the first trial clinic ap-
pointment, a more detailed confirmatory eligibility screen
will be completed by the investigator to document partici-
pants’ fulfilment of the entry criteria for all patients consid-
ered for the study and subsequently included or excluded.
A screening log will be kept to document details of
subjects who attend the trial clinic. For subjects who
decline participation, the log will record any reasons
specified for non-participation.
Patients taking acid suppressants, acid neutralisers or
alginates prior to involvement in/being approached to take
part in the TOPPITS trial must undergo a 4-week washout
period of PPIs or 24 hours for alginates or acid neutrali-
sers, before they start taking TOPPITS trial medication
(prescribed as part of Clinic Visit 1). Consent should be
taken prior to the washout period. Patients will be pro-
vided with a ‘washout period card’ confirming when the
washout period started, in case they attend a general prac-
titioner (GP) or clinic appointment prior to Visit 1. This
card can then be shown to the GP/consultant to try and
ensure the patient does not take/is not prescribed acid
suppressants, acid neutralisers or alginates.
Consent
Informed consent discussions will be undertaken by appro-
priate site staff (as per delegation log) involved in the study,
including medical staff and research nurses, with the oppor-
tunity for participants to ask any questions. Because pa-
tients will have already received the patient information at
their initial consultation (usually with a different physician
to that running the trial clinic) or through the post with an
invitation letter, and have taken the positive step to attend
the trial clinic, formal TOPPITS consent can be obtained at
the first dedicated trial clinic appointment. Those wishing
to take part will provide written informed consent by sign-
ing and dating the study consent form, which will be
witnessed and dated by a member of the research team
with documented, delegated responsibility so to do. Written
informed consent should always be obtained prior to ran-
domisation and prior to study specific procedures/investi-
gations. Those wishing to have further time to consider
may attend a subsequent clinic if they decide to participate.
The original signed consent form will be retained in the
Investigator Site File (ISF), with a copy in the clinical notes
and a copy provided to the participant. The participant will
specifically consent to their GP being informed of their par-
ticipation in the study.
The right to refuse to participate without giving reasons
must be respected.
Because of the small subject population, the patient
information sheet, consent form and questionnaires for
the study will be available only in English. Interpreters
may be arranged for all visits of patients who require
them either for verbal translation or for hearing-
impaired subjects wishing to take part in the study, via
local NHS arrangements. As per local custom, qualified
interpreters may be used to explain the consent form
and information sheet, and finding the most direct com-
munication will be a priority.
Outcomes
The RSI remains the ‘area standard’, and despite well-
rehearsed limitations [21] is therefore our chosen primary
outcome in the present proposal. Some reported studies
have a baseline RSI only just above the normal level, others
considerably higher. A Korean observational study of 455
patients reported that the mean RSI score fell from 15 at
baseline to <6 after 12 weeks of the PPI rabeprazole [22].
Baseline RSI scores in a much smaller but comparative
study of 62 patients treated with esomeprazole were con-
siderably higher (>20) [23], whereas baseline scores in a
rabeprazole randomised controlled trial were around 14
[13]. Two trials showed a benefit from a 3-month trial of
acid suppression – but Lam et al. [13] continued follow up
for a further 6 weeks, when the effect disappeared, while
Reichel et al.’s [24] final measurement point was the end of
therapy.
Throat symptoms impact on general health status
measures [25, 26]. A tool specifically designed to assess
throat symptom patients is the LPR-HRQL tool [27, 28],
which has also been validated in a Swedish population
[29]. Its 43 items are grouped into four domains and an
overall impact category, and the tool appears responsive
to change [30].
The TOPPITS primary outcome is the change in RSI
at 4 months in the treatment and placebo groups in an
intention-to-treat analysis. The nine-item RSI total
score (0–45) allows comparison with previous studies.
We plan, however, to report also the RSI score omitting
the heartburn item (0–40), which we and others note
can skew the results in favour of PPIs in past small tri-
als. Our proposed analysis will also address the issue of
severity variation, through our stratification variables of
site and baseline severity.
Secondary outcomes are as follows:
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 RSI changes as above, at 12 months after
randomisation.
 Quality of life: change in LPR-HRQL total score and
subscale at 4 and 12 months.
 Laryngeal mucosal changes—increased RFS—are
widely prevalent in both normal volunteers (64–86
%) [31] and in throat symptom patients (38–51 %).
The best predictor of EOR is pseudosulcus (67–
90 % positive predictive value) [32, 33], but this is
a rare finding. We propose to assess the RFS
scored 0–29 by an independent observer, blind to
treatment group as a response predictor, alongside
patient characteristics (age, gender, smoking, body
mass index) and the total, and the CReSS total
and three subscales—oesophageal (14 items),
upper airway (eight items) and pharyngeal (seven
items).
 Estimates of compliance (pill count), side effects and
current and/or planned use of over-the-counter
medication.
 Patient-reported satisfaction.
Success criteria
The following success criteria were set by the funder, to
assess continuation of the study after the first 6 months
of recruitment:
 Sites in Newcastle, Sunderland and Nottingham are
set up and recruiting.
 The study has recruited a minimum of 30
participants.
 Participants who have reached the first review dates
have not experienced any unforeseen problems with
prescribed medication.
The objectives of the internal pilot, set by the funder, are
as follows:
 To test the projected pathway for throat symptom
patients, including high-definition photography for
RFS scoring.
 To confirm that eligibility criteria are operational by
keeping an anonymous database characterising the
total population screened.
 To assess the acceptability and workability of the
proposed patient identification and recruitment
model.
 To quantify numbers of eligible research clinic
attenders and, of those, the number agreeing to be
randomised.
 To test whether all of the secondary outcome
measures (CReSS and LPR-HRQL) are appropriate.
 To design and test the data storage tools and
methods.
Data handling and record keeping
Data collected as part of this study, their quality and reten-
tion are the responsibility of the Chief Investigator, Profes-
sor Janet Wilson.
Data will be recorded by authorised site staff on elec-
tronic case report forms to allow statistical analysis of the
study to take place. Data transferred from site to the secure
validated database by remote access will be secure and
encrypted.
Data will be handled, computerised and stored in accord-
ance with the Data Protection Act 1998. No participant
identifiable data will leave the study site and participants
will be identified by unique study numbers.
Caldicott approval covers the collection, retention, stor-
age, transfer and use of personal identifiable information
in this trial, and all study data will be retained in accord-
ance with local policy and relevant Standard Operating
Procedures (SOPs).
Sample size calculation
The primary outcome measure is the change in the RSI
score from baseline to the 4-month assessment. We be-
lieve a clinical effect of 0.4 (equivalent to a difference in
change of RSI of 3.1 given a standard deviation of 7.7 [34])
is a reasonable target based on prior LPR therapy studies.
Further, an effect size of 0.4 is of smaller magnitude than
the effect of phonomicrosurgery or speech therapy. A
similar effect size is predicted from the more limited
amount of published data available on the LPR-HRQL.
For a two-sample t test, 90 % power and at the 0.05 sig-
nificance level, allowing for 20 % loss to follow-up, we re-
quire 332 patients (166 in each arm of the study) to give
266 (133 in each arm) completing the study. Two other
recent reports of LPR drug studies show lower than 7 %
dropout rates. Our NHS experience, however, suggests
that this is overly optimistic for a trial of this kind. Be-
cause the literature is well populated with underpowered
low-impact studies, we prefer to err on the side of caution
and hence our sample allows for a 20 % attrition rate.
Participant recruitment into the pilot phase will be for
a total of 6 months. We estimate that each site will be
able to recruit 10 participants per 3-month block once
the study is established. However, as research studies
usually take some time to become embedded into prac-
tice, we have calculated recruitment across the whole
trial based on lower recruitment in three sites during the
first 6 months. Our predicted recruitment allows for
each of the three sites to recruit 30 % (three partici-
pants) in the first 3 months, and 70 % (seven partici-
pants) in the second 3 months. We aim for those three
sites to be recruiting to full target (10 participants per 3
months) thereafter in the main trial, with equivalent
run-in for the remaining three sites.
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Study design and duration
This is a multi-centre, phase III, randomised, double-blind,
placebo-controlled trial, with internal feasibility pilot, car-
ried out in secondary care. Patients will be randomised into
two parallel streams on a 1:1 ratio stratified by site and
baseline severity (two groups, on the basis of the RSI score).
Following successful demonstration of recruitment in three
sites in the internal pilot, a definitive trial will be conducted
over 30 months. Patients with persistent throat symptoms
will be identified and recruited from ENTclinics.
Feasibility pilot
There will be an initial feasibility pilot, for 6 months,
during which three sites will recruit 10 participants
each. At the end of month 6, a report will be submit-
ted to the funder, National Institute for Health Re-
search (NIHR) Health Technology Assessment (HTA).
The criterion for stopping the trial early is the failure
to recruit 30 participants in the pilot, demonstrating
a lack of feasibility. Trial progress will be overseen by
the Data Monitoring and Ethics Committee (DMEC)
and Trial Steering Committee (TSC), and if this tar-
get is not reached the HTA will not release the full
funding.
Full trial
A further 302 participants (332 participants in total) will be
recruited over seven sites: Newcastle, Sunderland, Notting-
ham, Brighton, Glasgow, Manchester and Birmingham.
Intervention
The active intervention is a 16-week (4-month) course
of a 30 mg twice daily dose of the PPI lansoprazole.
Control
Participants in the control arm will receive a 16-week (4-
month) course of twice-daily matched placebo capsule.
Study compliance and withdrawal
Where feasible, visit windows of ±14 days should ensure
visit attendance; non-attendance for study visits will
prompt follow-up by telephone.
Compliance with study medication will be assessed by
checking and recording the remaining number of capsules
at the end of the treatment period by a member of the
study team. Study drug accountability will be assessed and
documented by local pharmacy before being destroyed.
Withdrawal of participants
Study drug must be discontinued if:
 the participant decides that he/she no longer wishes to
continue, or
 cessation of study drug is recommended by the PI.
Participants have the right to withdraw from the study
at any time for any reason, and without giving a reason.
The PI also has the right to withdraw participants from the
study drug in the event of intervening pregnancy, inter-
current illness, adverse events, serious adverse events,
suspected unexpected serious adverse reactions, protocol
violations, cure, administrative reasons or other reasons. It
is understood by all concerned that an excessive rate of
withdrawals can render the study uninterpretable; therefore,
unnecessary withdrawal of participants should be avoided.
Should a participant decide to withdraw from the study, all
efforts will be made to report the reason for withdrawal as
thoroughly as possible. Should a participant withdraw from
the study drug only, efforts will be made to continue to
obtain follow-up data, with his/her permission.
Participants who wish to withdraw from study medica-
tion will be asked to confirm whether they are still willing
to provide the following:
 Study-specific data at follow-up visits at 4 and 12
months.
 ‘End of study data’ as per the visit at 12 months, at
the point of withdrawal.
 If participants agree to either of the above, they will
be asked to complete a confirmation of withdrawal
form to document their decision.
Participants who withdraw from the study will not be
replaced.
Statistical analysis
The primary outcome measure of change in RSI score
after 4 months will be analysed using analysis of covari-
ance (ANCOVA) methods in order to compare the
change in RSI between the trial arms while adjusting for
potential confounders including the stratification vari-
ables used at randomisation of site and baseline severity
(as defined by the binary RSI cutoff value) as covariates
in the analysis. We will also consider adjusting for gender,
age, body mass index, baseline laryngeal appearance
scores by the RFS and categories of symptoms. Not all of
these covariates mentioned will necessarily be included in
the final model but will be considered during the model
selection process.
Should data be found to be non-normally distributed the
use of transformations or non-parametric approaches will
be considered, although as ANCOVA is generally robust to
departures from normality the aforementioned approach is
likely to be followed. More basic exploratory analyses
may be undertaken using the two-sample t test or non-
parametric alternatives.
The analysis of secondary outcomes will follow a broadly
similar strategy when considering questionnaire scores or
the change in questionnaire scores. The proportion with
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follow-up RSI scores within versus out with the published
normal range will be analysed using a logistic regression
approach, once more adjusting for the covariates as already
described for the primary outcome.
The primary analysis will be carried out on an intention-
to-treat basis; other analysis groups, such as per protocol,
may be considered subsequently. Outcome data will be
analysed at the end of the study. There are no planned
interim analyses and a full statistical analysis plan will be
developed prior to the start of analysis. Safety data will not
be subject to statistical analysis. Data with missing observa-
tions due to loss to follow-up will be examined to deter-
mine both its extent and whether it is missing at random
or is informative. If data are missing to a sufficient extent,
the use of appropriate multiple imputation techniques will
be considered.
Study monitoring
Trial Management Group
The trial will be managed by a Trial Management Group
(TMG) consisting of key staff members at the Newcastle
Clinical Trials Unit, together with selected investigators,
and will meet monthly throughout the set up and duration
of the study.
Trial Steering Committee
A TSC will be established to provide overall supervision of
the trial. The TSC will consist of the Chief Investigator (CI),
an independent chairperson, an independent clinician, two
public members, an independent statistician and observer
members of the TMG. The committee will meet prior to
the start of the internal pilot, and then annually during re-
cruitment and for the duration of the trial.
Data Monitoring and Ethics Committee
An independent DMEC will be convened to undertake
independent review and will monitor efficacy and safety
endpoints. The committee will consist of an independent
chairperson, an independent clinician and an independent
statistician, and will meet to discuss and advise on the
inclusion of an interim analysis and possible adoption of a
formal stopping rule for efficacy or safety. The committee
will then meet at the end of the internal pilot and annually
throughout the course of the trial.
Ethical approval and confidentiality
The conduct of this study will be in accordance with the
recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical
Assembly, Helsinki 1964 and later revisions. All members
of the research team and the investigators at each of the
participating sites will be trained in those aspects of Good
Clinical Practice appropriate to their role in the trial.
A favourable ethical opinion was granted by the NRES
Committee—North East: Tyne and Wear South (reference
number: 13/NE/0336), and a Clinical Trial Authorisation
granted by the Medicines and Healthcare Products Regula-
tory Agency, prior to commencement of the study. Local
approvals are sought before recruitment commences at
each site. The Newcastle Clinical Trials Unit in its capacity
as The Study Co-ordination Centre requires a written copy
of local approval documentation before initiating each site
and accepting participants into the study.
Information sheets will be provided to all eligible subjects.
Eligible subjects may also be given access to a DVD that
explains more about the study. Written informed consent
will be obtained prior to any study procedures.
Safeguarding confidentiality
Personal data will be regarded as strictly confidential. To
preserve anonymity, any data leaving the site will identify
participants by a unique study identification code only.
The study will comply with the Data Protection Act 1998.
All study records and ISFs will be kept at site in a locked
filing cabinet with restricted access.
Long-term data storage
At the end of the study, original questionnaires, case report
forms and consent forms will be securely archived for 15
years following publication of the last paper or report from
the study, in line with sponsor policy and standard operat-
ing procedures. This will allow any queries or concerns
about the data, conduct or conclusions of the study to be
resolved.
Discussion
Throat symptoms represent a significant health issue, and
there is wide uncertainty on PPI use among clinicians,
GPs and patients. In assessing changes in symptoms and
in overall quality of life, the TOPPITS trial will provide a
clear assessment of their use, in a randomised, placebo-
controlled trial, and robust information on their use.
Trial status
At the time of manuscript submission, 201 participants
have been recruited to the trial and it remains open to
recruitment.
Additional files
The following documents were submitted with this proto-
col for publication: CONSORT 2010 checklist of informa-
tion to include when reporting a randomised trial (see
Additional file 1), and Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) 2013 Check-
list—recommended items to address in a clinical trial
protocol and related documents (see Additional file 2).
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Additional file 1: presents the CONSORT 2010 checklist of information
to include when reporting a randomised trial, completed for TOPPITS.
(PDF 43 kb)
Additional file 2: presents the SPIRIT 2013 Checklist—recommended
items to address in a clinical trial protocol and related documents
completed for TOPPITS. (PDF 35 kb)
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